NCT03220035 2025-01-27Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Completed4 enrolled 12 charts